Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Francesca Spada, MD, Istituto Europeo di Oncologia, Milan, Italy, discusses updates in neuroendocrine neoplasms at the European Society for Medical Oncology (ESMO) 2026 Congress, highlighting the evolution of nuclear medicine in well-differentiated tumors, the use of new antibodies in poorly differentiated neoplasms, and the growing importance of biomarkers. The congress featured promising results from a Phase I/IIa trial (NCT05636618) assessing [212Pb]VMT-a-NET and the use of new antibodies targeting PD-L1 and VEGF-A. This interview took place at the ESMO 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.